IRVINE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will present at the Bank of America 2023 Healthcare Conference on Tuesday, May 9, 2023 at 3:00 p.m. Pacific Time at the Encore Hotel in Las Vegas.
A live audio webcast and replay of the presentation may be accessed for 90 days on the “Investor Relations” section of the company’s website at: https://www.inarimedical.com/.
About Inari Medical, Inc.
Patients first. No small plans. Take care of each other. These are the guiding principles that form the ethos of Inari Medical. We are committed to improving lives in extraordinary ways by creating innovative solutions for both unmet and underrecognized health needs. In addition to our purpose-built products, we leverage our capabilities in education, clinical research, and program development to improve patient outcomes. We are passionate about our mission to establish our treatments as the standard of care for venous thromboembolism and beyond. We are just getting started.
Investor Contact:
ICR Westwicke
Caroline Corner
Phone +1-415-202-5678
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$79.97 |
Daily Volume: | 0 |
Market Cap: | US$4.680B |
January 03, 2025 December 02, 2024 December 02, 2024 October 29, 2024 October 28, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load